|本期目录/Table of Contents|

[1]毛幼林,黄琼,袁义强,等.基因重组人脑利钠肽治疗心力衰竭伴肺动脉高压的临床研究[J].慢性病学杂志,2015,(6):623-625.
　MAO You-lin,HUANG Qiong,YUAN Yi-qiang,et al.Effects of intravenous recombinant human brain natriuretic peptide in patients with pulmonary hypertension complicated with heart failure[J].,2015,(6):623-625.
点击复制

基因重组人脑利钠肽治疗心力衰竭伴肺动脉高压的临床研究(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2015年6期
页码:
623-625
栏目:
论　著
出版日期:
2015-12-27

文章信息/Info

Title:
Effects of intravenous recombinant human brain natriuretic peptide in patients with pulmonary hypertension complicated with heart failure
作者:
毛幼林;  黄琼;  袁义强;  于力
郑州市第七人民医院（郑州市心血管病医院心内科），郑州450000
Author(s):
MAO You-lin;  HUANG Qiong ;  YUAN Yi-qiang;  YU Li
Cardiology Department of Zhengzhou No.7 Hospital，Zhengzhou, Henan 450000, China Corresponding author: MAO You-lin, E-mail: mohdmao2004@hotmail.com
关键词:
心力衰竭; 肺动脉高压; 脑利钠肽; 血流动力学
Keywords:
Heart failure;  Pulmonary hypertension;  Natriuretic peptide;  brain;  Hemodynamics
分类号:
R135
DOI:
-
摘要:
目的观察基因重组人脑利钠肽(rhBNP)治疗心力衰竭伴肺动脉高压的效果。方法40 例心力衰竭 伴肺动脉高压患者,随机分为静脉滴注rhBNP 组和对照组，每组20 例。两组患者均给予降低肺动脉压及改 善心功能等基础治疗。比较用药前及用药48 h 后两组患者有创血流动力学参数、左心功能、肺动脉压、不 良反应和治疗2 周内的主要不良心脏事件(MACE)的发生情况。采用SPSS 15.0 软件处理；计量资料采用 配对t 检验，计数资料用χ2 检验，P<0.05 为差异有统计学意义。结果rhBNP 组和对照组间及用药前后中 心静脉压(CVP)和收缩压(SBP)无明显变化。rhBNP 组用药48 h 后的肺毛细血管楔压(PCWP)较对照组明显 降低（P<0.05）。2 周后，rhBNP 组左室射血分数及肺动脉压较对照组显著改善（P<0.05）。本研究未发现 严重不良反应，仅发现1 例与rhBNP 相关的症状性低血压。两组治疗2 周内的主要心血管事件的发生情况 相似。结论对于心力衰竭伴肺动脉高压患者，滴注rhBNP 可降低PCWP，改善心功能，可明显改善患 者症状，但不影响血流动力学，是安全有效的治疗心力衰竭伴肺动脉高压的药物。
Abstract:
Objective To investigate the effects and safety of nesiritide, i.e., a recombinant human Btype natriuretic peptide (rhBNP) in patients with pulmonary hypertension complicated with heart failure. Methods Hospitalized patients with pulmonary hypertension complicated with heart failure (40 cases) were randomly divided into rhBNP- treated group (n=20) and no treatment control group (n=20). The two groups both received the basic treatment to decrease pulmonary hypertension, improve heart function. The hemodynamic parameters were monitored using Swan- Ganz catheter before and at 48 hours after drug infusion. The major adverse cardiac events (MACE), pulmonary artery pressure (PAP) and left ventricular ejection fraction (LVEF) were monitored up to 2 weeks after drug infusions. Results Central venous pressure and systolic blood pressure were unchanged with or without rhBNP infusion. Compared to the control group without infusion, PAP of the rhBNP-treated group was significantly reduced after treatment. After 2 weeks, LVEF and PAP of the rhBNP- treated group significantly improved, in comparison to the group. Other than 1 case of rhBNP associated symptomatic hypotension, no adverse events were observed during drug infusion. MACE up to 2 week post drug infusion was also similar to that of the untreated control. Conclusions In patients hospitalized with pulmonary hypertension complicated with heart failure, nesiritide improves hemodynamic function and clinical status, and deceases PCWP. Therefore, nesiritide is effective and safe for the treatment of pulmonary hypertension complicated with heart failure.

参考文献/References:

[1] Ahluwalia A, MacAllister RJ, Hobbs AJ. Vascular actions of natriuretic peptides. Cyclic GMP- dependent and - indepen? dent mechanisms [ J]. Basic Res Cardiol, 2004,99(2):83-89. [/br]［2］ Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemo? dynamic effects of an infusion of nesiritide (human b-type natri? uretic peptide) in heart failure: a randomized, double- blind, placebo- controlled clinical trial [ J]. J Am Coll Cardiol, 1999, 34(1):155-162. [/br]［3］ Yancy CW, Krum H, Massie BM, et al. The Second Followup Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design [J]. Am Heart J,2007, 153(4):478-484. [/br]［4］ Colucci WS, Elkayam U, Horton DP, et al. Intravenous ne? siritide, a natriuretic peptide, in the treatment of decompensat? ed congestive heart failure [J]. N Engl J Med, 2000,343(4): 246-253. [/br]［5］ Publication Committee for the VMAC Investigators. Intrave? nous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial [J]. JA ? MA, 2002,287(12):1531-1540.[/br]［6］ Davie NJ, Schermuly RT, Weissmann N, et al. The science of endothelin- 1 and endothelin receptor antagonists in the man? agement of pulmonary arterial hypertension: current under? standing and future studies [J]. Eur J Clin Invest, 2009,39 (2): 38-49. [/br]［7］ Khush KK, De Marco T, Vakharia KT, et al. Nesiritide Acutely Increases Pulmonary and Systemic Levels of Nitric Oxide in Patients With Pulmonary Hypertension [J]. J Card Fail, 2006,12(7):507-513. [/br]［8］ Maack T. Role of atrial natriuretic factor in volume control [J]. Kidney Int, 1996,49(6):1732-1737.

备注/Memo

备注/Memo:
作者简介：毛幼林，硕士，副主任医师，研究方向：心血管病的诊治 通信作者：毛幼林，E-mail：mohdmao2004@hotmail.com
更新日期/Last Update: 2015-12-27